Close Menu

Quidel

The US Food and Drug Administration has granted 510(k) clearance to Quidel's Molecular Influenza A+B and RSV+hMPV assays for use on Life Technologies' QuantStudio Dx real-time PCR instrument, the companies said this week.

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has granted 510(k) clearance to Quidel's Molecular Influenza A+B and RSV+hMPV assays for use on Life Technologies' QuantStudio Dx Real-Time PCR instrument, the companies said today.

NEW YORK (GenomeWeb News) – Quidel reported after the close of the market Tuesday that its second-quarter revenues declined 4 percent year over year, due primarily to lower sales of its infectious disease diagnostic products.

NEW YORK (GenomeWeb News) – The mergers and acquisitions market in the omics tools and molecular diagnostics space continues to be soft as the number of deals fell 11 percent year over year during the first half of 2013.

With its acquisition this week of privately held molecular diagnostic developer BioHelix, clinical diagnostics firm Quidel adds to its portfolio of technologies to enable its burgeoning molecular diagnostics business.

NEW YORK (GenomeWeb News) – Clinical diagnostics firm Quidel said today that it has acquired BioHelix.

Quidel said this week that increased flu testing and subsequent demand for its respiratory diagnostic tests — including its relatively new Quidel Molecular portfolio — helped drive a 63 percent year-over-year spike in first-quarter revenues.

NEW YORK (GenomeWeb News) – Quidel reported after the close of the market on Tuesday that its revenues in the first quarter increased 63 percent year over year.

NEW YORK (GenomeWeb News) – SynapDx this week said that it has received a "significant investment" from The Kraft Group that will support ongoing clinical development of its molecular diagnostic test for autism spectrum disorder.

Life Technologies and Quidel said this week that they have received 510(k) clearances from the US Food and Drug Administration to market the Quidel Molecular Direct C.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.